PL2094254T3 - Leczenie kacheksji - Google Patents

Leczenie kacheksji

Info

Publication number
PL2094254T3
PL2094254T3 PL07824794T PL07824794T PL2094254T3 PL 2094254 T3 PL2094254 T3 PL 2094254T3 PL 07824794 T PL07824794 T PL 07824794T PL 07824794 T PL07824794 T PL 07824794T PL 2094254 T3 PL2094254 T3 PL 2094254T3
Authority
PL
Poland
Prior art keywords
cachexia
treatment
prevention
receptors
tertatolol
Prior art date
Application number
PL07824794T
Other languages
English (en)
Inventor
David Cavalla
Original Assignee
Actimed Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimed Therapeutics Ltd filed Critical Actimed Therapeutics Ltd
Publication of PL2094254T3 publication Critical patent/PL2094254T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
PL07824794T 2006-12-05 2007-12-05 Leczenie kacheksji PL2094254T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0624282.0A GB0624282D0 (en) 2006-12-05 2006-12-05 Treatment of cachexia
EP07824794A EP2094254B1 (en) 2006-12-05 2007-12-05 Treatment of cachexia
PCT/GB2007/004644 WO2008068477A1 (en) 2006-12-05 2007-12-05 Treatment of cachexia

Publications (1)

Publication Number Publication Date
PL2094254T3 true PL2094254T3 (pl) 2011-12-30

Family

ID=37671884

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07824794T PL2094254T3 (pl) 2006-12-05 2007-12-05 Leczenie kacheksji

Country Status (16)

Country Link
US (1) US8716325B2 (pl)
EP (2) EP2094254B1 (pl)
JP (1) JP5166437B2 (pl)
CN (1) CN101610760B (pl)
AT (1) ATE513543T1 (pl)
AU (1) AU2007330607B2 (pl)
BR (1) BRPI0720114A8 (pl)
CA (1) CA2671622C (pl)
DK (1) DK2094254T3 (pl)
ES (1) ES2395244T3 (pl)
GB (1) GB0624282D0 (pl)
PL (1) PL2094254T3 (pl)
PT (1) PT2094254E (pl)
RU (1) RU2485950C2 (pl)
WO (1) WO2008068477A1 (pl)
ZA (1) ZA200904704B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907350D0 (en) 2009-04-29 2009-06-10 Myotec Therapeutics Ltd Methods
BR112015001712A2 (pt) * 2012-07-25 2017-07-04 Psioxus Therapeutics Ltd uso de s-pindolol para o tratamento da caquexia e sarcopenia
HRP20182041T1 (hr) * 2013-03-14 2019-02-08 Actimed Therapeutics Ltd Pripravci oksprenolola za liječenje raka
US11096908B2 (en) 2016-02-26 2021-08-24 Actimed Therapeutics Ltd S-enantiomerically enriched compositions of beta blockers for treating muscle weakness
GB2593902B (en) 2020-04-07 2022-04-13 Actimed Therapeutics Ltd Salt of a pharmaceutical compound
GB202114564D0 (en) 2021-10-12 2021-11-24 Actimed Therapeutics Ltd Oral formulation
WO2025222169A1 (en) 2024-04-19 2025-10-23 Faraday Pharmaceuticals, Inc. S-oxprenolol for preserving muscle mass, bone density, and cardiac function in weight loss treatments

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541188A (en) 1987-09-15 1996-07-30 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
CA1337432C (en) 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
US6545040B1 (en) 1988-03-23 2003-04-08 Janssen Pharmaceutica N.V. Method of lowering the blood pressure
CA2025398A1 (en) 1989-09-20 1992-03-15 Timothy Gerard Dinan Diagnosis and treatment of a disorder of the gastrointestinal tract
US5120791A (en) 1990-07-27 1992-06-09 Lisco, Inc. Golf ball cover compositions
DE69942009D1 (de) 1998-10-15 2010-03-25 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
HUP0204262A2 (hu) 2000-01-31 2003-04-28 Pfizer Products Inc. Benzogyűrűvel kondenzált heterociklusos csoportot tartalmazó nikotinamid-származékok, továbbá e vegyületeket tartalmazó, a PDE4 izozimek szelektív gátlására adható gyógyászati készítmények
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
WO2003065970A2 (en) * 2001-02-20 2003-08-14 Royal College Of Surgeons Ie Treatment of fibromyalgia and related fatigue syndromes using pindolol
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
WO2006030306A2 (en) * 2004-09-17 2006-03-23 Neurocure Ltd Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder
US20060069086A1 (en) 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2646131C (en) 2005-03-21 2018-09-04 Vicus Therapeutics Spe 1, Llc Compositions and methods for ameliorating cachexia
MX2008007790A (es) 2005-12-22 2009-03-04 Anaborex Inc Composiciones y metodos para la prevencion y tratamiento de caquexia.
WO2007100775A2 (en) 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CL2007003227A1 (es) 2006-11-09 2008-07-04 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo en combinacion con uno o mas agentes terapeuticos; y uso para el tratamiento de diabetes mellitus, obesidad e hiperglucemia entre otras.
KR101546977B1 (ko) 2007-04-24 2015-08-24 아카시아 파마 리미티드 근육 손실의 치료에서의 약물 조합 및 그것의 용도
CA2753844A1 (en) 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies

Also Published As

Publication number Publication date
ES2395244T3 (es) 2013-02-11
CA2671622C (en) 2015-01-27
EP2359822B1 (en) 2016-08-03
AU2007330607A1 (en) 2008-06-12
US8716325B2 (en) 2014-05-06
JP5166437B2 (ja) 2013-03-21
EP2094254A1 (en) 2009-09-02
DK2094254T3 (da) 2011-10-03
EP2359822A1 (en) 2011-08-24
AU2007330607B2 (en) 2013-02-07
EP2094254B1 (en) 2011-06-22
ZA200904704B (en) 2010-05-26
WO2008068477A1 (en) 2008-06-12
RU2009125548A (ru) 2011-01-20
CA2671622A1 (en) 2008-06-12
BRPI0720114A8 (pt) 2016-01-19
CN101610760A (zh) 2009-12-23
RU2485950C2 (ru) 2013-06-27
GB0624282D0 (en) 2007-01-10
US20100292270A1 (en) 2010-11-18
JP2010511685A (ja) 2010-04-15
CN101610760B (zh) 2012-09-26
ATE513543T1 (de) 2011-07-15
BRPI0720114A2 (pt) 2014-04-15
PT2094254E (pt) 2011-09-19

Similar Documents

Publication Publication Date Title
ZA200904704B (en) Treatment of cachexia
MX2009009537A (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
NO20090623L (no) Forbindelser for behandling av proliferative lidelser
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
NO20091260L (no) Kombinasjonsbehandling for diabetes mellitus
GT200600046A (es) Terapia de combinacion
PL1979355T3 (pl) Pochodne spiro imidazoli jako modulatory PPAR
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
TNSN08284A1 (en) Masking the taste of powders
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
CY1117860T1 (el) Διαβλεννογονια χορηγηση 2-(10-υδροξυδεκυλ)-5,6-διμεθοξυ-3-μεθυλ-2,5-κυκλοεξαδιενο-1,4-διονης (ιδεβενονη)
WO2008075201A3 (en) Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
WO2007075825A3 (en) Lipophilic anticancer drug compounds
MY157425A (en) Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
WO2008087329A3 (fr) Nouveau médicament pour le traitement d'un cancer gastrique
WO2007104933A8 (en) Chemical compounds
MY150776A (en) Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria
WO2007011958A3 (en) Intraoral dosage forms of glucagon
WO2008005806A3 (en) Therapeutic methods, compositions, and compounds
MX2007007183A (es) Aminas, combinacion de aminas y vanadio y sales de amina y vanadio para el tratamiento o prevencion de dislipidemia.